Device Trial Radar · NCT03396172
FreeDom: Innovative Strategy for the Management of COPD Exacerbations
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 24, 2018
Primary completion
Jun 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Laval UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 10, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study is to assess the "FreeDom" innovative strategy (FreeO2 at Domicile) to reduce hospitalization duration in patients with COPD exacerbation. This strategy associates early hospital discharge, automated O2 flow weaning with FreeO2 system, telemedicine and tele-rehabilitation. The main hypothesis of this study is that the FreeDom strategy will reduce the number of hospitalization day by 50 percent at day 30.
Conditions
- Oxygen Deficiency
- COPD Exacerbation
Interventions
ControlOther
The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
FreeDomDevice
Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of hospital days during COPD exacerbation at day 30.Time frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.